Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Assistance Publique - Hôpitaux de Paris
Main objective: Compare the response rate after 6 months of hormone treatment (or a major change in hormone treatment) in metastatic breast cancer, according to the uptake of FES in metastatic lesions taking-up FDG on PET/CT at baseline.
Secondary objectives:
* evaluate diagnostic performance of FES PET/CT
* determine whether FES PET/CT is able to detect metastases that are not visible on FDG PET/CT. This point may constitute a direct benefit for the patient
* precise the nature of discordant FES/FDG foci
* validate and improve the interpretation criteria for FES PET/CT
* confirm the perfect tolerance
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Post menopausal
age \> 17
WHO 0-2
Metastatic adenocarcinoma of the breast
Treated by antihormone treatment during around 5 years withdrawn for at least 3 months OR metastatic cancer at diagnosis having received no more than one line of hormone treatment
Life expectancy \> 6 months
Hormone-dependent cancer initially demonstrated by hormone receptors in the tumour
Presence of oestrogen receptors proven with immunohistochemistry (\> 10%) and HER2 determined by immunohistochemistry or FISH (on primary tumour or a metastasis)
Metastatic recurrence on FDG PET dating less than 1 month, confirmed by another modality (contrast-enhanced CT, MRI, ultrasonography, bone scintigraphy or PET/CT, other)
FDG PET/CT available on PACS or CD DICOM III format 11
Informed consent obtained
You may not be if
Other evolutive malignant disease or acute or chronic infectious disease
Chemotherapy during the last 3 months or change in treatment since FDG PET/CT.
Isolated liver metastasis (high FES uptake by normal liver)
Clareo Health | Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer
